Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]AlF-NOTA-KR12C
- Development stage
- Preclinical
- Lead developer
- Nanfang Hospital, Southern Medical University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
[18F]AlF-NOTA-KR12C is a novel peptide-based positron emission tomography (PET) radiotracer designed for the non-invasive, real-time in vivo imaging of G-quadruplex (G4) secondary structures in solid tumors. Developed by researchers at Southern Medical University and Guangdong University of Technology, the tracer consists of the KR12C peptide (a mutant of the human cathelicidin LL37-derived FK13 peptide) conjugated to a NOTA chelator and radiolabeled with fluorine-18 via aluminum fluoride ([18F]AlF) chemistry. It specifically binds to G-quadruplex structures, such as the telomeric G-quadruplex 4Telo21 and the c-MYC promoter G-quadruplex Pu27, which are highly prevalent in various malignancies. In preclinical studies, [18F]AlF-NOTA-KR12C demonstrated favorable tumor-targeting properties, rapid clearance from non-target organs, and high tumor-to-background ratios in breast, liver, and cervical cancer models, making it a promising candidate for broad-spectrum cancer imaging.
- Other names
- 18F-AlF-NOTA-KR12C[18F]AlF-labeled NOTA-KR12C
02
Targets
telomeric G4 (Telomeric DNA G-quadruplex)
Beyond the preview
Go deeper on [18F]AlF-NOTA-KR12C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]AlF-NOTA-KR12C.